Novartis is splitting its pharmaceuticals division into two business units, one focused on cancer and the second on other drugs, while switching out its current pharma head in the second high-profile management reshuffle this year.
{iframe}http://www.reuters.com/article/us-novartis-restructuring-idUSKCN0Y81ZB{/iframe}